Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great news should be shared with Barron's, Forbes, the WSJ in print, and/or Fortune if the company wants to go to the next level of communication. An actual interview with Zoutman could supplement company press releases and be dynamite.
Marketwatch on-line coverage helps, but the WSJ in print would have been the coup d'etat. Yesterday and this morning's volume tells us that few people were reached and even fewer reacted, and the company remains below most radar screens.
Don't know what else to say about it. I looked very closely, several times, at the on-line WSJ for Tuesday and Wednesday and didn't see it. I am going to assume that many people still read it in print version while traveling. There was very little reaction to the press release. Not being in the print version had to hurt. That's why I thought it might have been bogus.
Just curious. I was on the WSJ on line this morning and did not see the article in either the Tuesday morning or Wednesday morning edition.
So...TG.....I have a print copy of Tuesday's WSJ in front of me. No article. Your copy has one line in red that says the WSJ had nothing to do with the creation of content of the article. So who forged it and why? What was the purpose?
Hopefully the "fine-print" data in the test results just released will give WW a comparison for its own findings and also give WW a little more ammunition with which to address potential customers which might generate a sale someday. Doc Shannon really did hit one nail square on the head: "....it's been a long time coming..."
Years ago the FDA began charging the industries, over which it has jurisdiction, fees (on the sale of approved products) to improve oversight, hire reviewers, and expedite processes. GTHP obviously has fallen through those cracks. Maybe it's back to an active review status merely because the company reminded the FDA that it needed a decision. If that's the case, we could be looking at several more months of nonsense. I truly believe the FDA knows it has to approve this test....but it doesn't want to do it because of the lost revenue this highly automated test will create in the areas of adjacent testing. It's what the auto and steel employees have endured for 40 years of technological innovation: Machine vs. manpower with improved productivity, safety, and product as prime results.....but fewer jobs
Ah....music to my ears G.O. I am happy to see someone else voice frustration over the lack of full test results after fifteen months. Positive results could have supplemented the EPA and USPTO applications and helped move the process forward.
I actually did receive an email reply that said, short and sweet, GTHP had heard nothing from the FDA.
I received the email this morning. This PR is merely a continuation of the fact that product finally was shipped somewhere: Turkey; not England, Germany or Canada. My email reply asked for an update on matters US and why there are continued delays.
Did you all happen to read the two "comments" under the article?
Okay you all....I am tired of looking at my own posts. Somebody pipe up and tell us what you know or perceive. This stock is just not acting right given what we're awaiting.
It's okay. I had a pretty good idea what you had in mind. Once the company gets through these long, drawn out, pesky regulatory issues and can actually concentrate on production introduction, the idea of having different sizes with different applications and dispersant feeder systems can seem very real. There are some very smart people at WW, and I imagine some of those ideas already have permeated their creative beings.
The PMA amendment filing was 11-13-12 at the latest, correct? So we are at least 7 1/2 months into the six month required reply period for the FDA.
Well, G.O., I am not at all versed in the area of detonators and explosions, so I will have to leave that invention up to you. Ha ha ha. The concept of a computer triggering a dispersement (explosion) capable of knocking out mold from large rooms, however, is an intriguing thought. I do not know what the effective carry would be for AS, but I would think that large areas like meeting rooms, etc. would require more than one application.
A portable version of AS would be terrific at some point for mold eradication. New Jersey must have its share of mold problems, and the Gulf Coast still has mold issues years after Ivan, Dennis, Rita, and Katrina blew through the area.
Is the R/S a done deal or still just speculation?
I think there is a lot of gray area here. 13d-6 doesn't even refer to a company being either required or not required to declare beneficial ownership.
Hey Elis.....what are your thoughts on this passage?
Legal Information Institute Cornell University School of Law
240.13d-6 Exemption of certain securities
The acquisition of securities of an issuer by a person who, prior to such acquisition, was a beneficial owner of more than five percent of the outstanding securities of the same class as those acquired shall be exempt from section 13(d) of the Act: PROVIDED, That:
a. The acquisition is made pursuant to preemptive subscription rights in an offering made to all holders of securities of the class to which the preemptive subscription rights pertain;
b. Such person does not acquire additional securities except through the exercise of his pro rata share of the preemptive subscription rights; and
c. The acquisition is duly reported, if required, pursuant to section 16(a) of the Act and the rules and regulations thereunder.
The U. of Miami medical school commentary was powerful. Should one suppose that the FDA is more concerned about the efficiency and cost savings that will be created by the approval, thereby stepping on the toes of some its big buddies, instead of the life saving qualities of this diagnostic test?
No one has to be privy to C3's business formation to know it hasn't placed any reorders.
Where are the revenues from C3 for the last year?
So...Elis......what does this situation tell us?
The 13D filing is "supposed" to allow shareholders to see who holds the beneficial interest in a company.
You may have saved me some time. I was going to go into the "Edgar" search engine and start checking it out.
From the SEC: "When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934, they are required to file a Schedule 13D with the SEC. Schedule 13D reports the acquisition and other information within ten days after the purchase. The schedule is filed with the SEC and is provided to the company that issued the securities and each exchange where the security is traded. Any material changes in the facts contained in the schedule require a prompt amendment."
This is the first time I didn't sell when it got back into the .90s. We have to be very close to a game changing decision, one way or the other. The FDA is overdue, even by its own standards, on this one.
One of the great historical markers of developing a business plan is using the completed market research to assess the future demand for the product once it becomes available......based on what potential customers tell you. 2009-11 would have been the ideal time to write that plan. The "if we build it, people will trample each other to buy it" plan obviously didn't work. All the regulatory approvals will be nice, but they won't necessarily translate into revenue. WIV has hit the nail on the head once again. We are all told so very little, when one gets right down to it. Those supposed "updates" we receive quarterly really don't tell us much in the way of new news. They rehash old news and inform us of continuing delays in important areas. So I am writing off 2013 and hope that WW, and maybe even C3, will have developed some kind of plan that will put them in front of potential customers going into 2014. So....we're all on a bus being passively driven by an invisible Floridian? Hmmmmmmm.
That's too bad. We need a lot more dialogue on this board.
Elis...thanks for all the recent help on the USPTO and EPA issues. Hopefully those two issues plus the issues of testing will be completed with favorable outcomes. Shareholders really should settle for no less than a relentless pursuit of revenues at this stage of the game. No one, however, seems to know what kind of time frame we are looking at from here. Any guesses?
Hey tbird....there appears to be something desperately wrong with TRIT after I read that first quarter report. They should be kicking butt given the idustry and where they try to gather contracts. What's your take?
So what's up with this thing above $2.50?
That article came in an email this morning from Guided. The article was based in London. Guided just isn't on anyone's radar...especially biotech/healthcare mutual funds. If institutions were aware, this stock price would be a bit higher.
Your corporate history and expertise in the pharma/bio area is having an immediate positive impact on this board. You and I probably will continue to politely disagree on a few issues of fundamental business principles as it relates to corporate governance. Having watched this company since 1987 and having attended shareholder meetings back when they held them, I am thrilled that Medizone actually has a shot at commercialization of a product. Time, however, always is of the essence, and competitors with inferior product but superior corporate oversight have managed significant market penetration. Management's need to be relentless in today's efforts cannot be overstated. Allowing a several month delay in safety and efficacy testing procedure, without having an alternate site for continuance, is not my idea of "best practice". I don't post every day and am going back into hibernation for a few weeks. Don't get me wrong. I am more excited about Medizone's prospects now than at any point in the last 26 years. I want to see a delay-free relentless pursuit at this point, and I think other long term shareholders want the same thing.
I believe most of the shareholders can agree with you on some of the issues. I'm looking at the progress of the last 12 months, however, and wishing a Balzer-type would have been hired four years ago. Being a measurment stickler, I think it's unconscionable that a company would delegate its business plan to would-be distributors when there was a five year period to do market research and establish potential penetration levels for eight sub-industry groups for the product. Talk about delays. Nothing incurs more delay and inaction than the lack of viable business plan.
I have proudly cast my vote AGAINST all issues
Our comparisons make the continued delay of U.S. approval for GTHP seem even more outrageous. It doesn't have the issues those other companies have. Hemispherx conducted a bush league test, and it doesn't factor in depression as a deterrent to its success even though many people swear by its efficacy......problems with which GTHP does not have to deal. The whole world is behind GTHP. Other mentioned companies have had testing protocol and potential safety issues....again not a worry for GTHP. I don't get it.
Elis.....would having completed positive test results in hand from Belleville be enough to sway the EPA regarding the safety issues and the USPTO as to the efficacy issues? The USPTO is using Centanni as the benchmark. Who's to say that Asepticsure shouldn't be the benchmark? A 7.00 log kill is a 7.00 log kill anyway we look at it.
.......really scratching my head about this situation. Why....really....was it turned down the first time? Did it look too good to be true? Was it going to cut out series of older, more invasive, diagnostic tests that no longer would be needed? Is an 86% success rate on diagnosis not high enough (yeah right)? Is it because one of the big boys didn't invent it? Did the right people not get paid? It does make one wonder about the FDA. CHTP has had a Parkinsons related product on the market in Japan for 15 years and has been given pure FDA runaround trying to get it approved here. MZEI has a decontamination system for hospitals and many other applications that is registering 7.00+ log kill rates for every bacteria in the book that causes HAIs. USPTO is not being cooperative (but things in Canada are getting ready to ramp up big time). BPAX has a testosterone based therapy for women but the FDA would rather allow rogue, off radar, access to inferior unregulated product to continue. I just don't get it.
Where are the test results?